BeiGene Ltd ADR buy marge
Start price
06.11.17
/
50%
€83.33
Target price
01.01.19
€198.44
Performance (%)
51.83%
End price
01.01.19
€126.51
Summary
This prediction ended on 01.01.19 with a price of €126.51. With a performance of 51.83% the BUY prediction by marge was a big success. marge has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
BeiGene Ltd ADR | 11.538% | 11.538% | -37.500% | -50.680% |
iShares Core DAX® | -0.992% | -3.231% | 11.661% | 16.545% |
iShares Nasdaq 100 | -0.225% | -3.339% | 36.491% | 43.334% |
iShares Nikkei 225® | -0.736% | -7.859% | 18.597% | 4.253% |
iShares S&P 500 | -0.509% | -2.979% | 26.341% | 40.911% |
Comments by marge for this prediction
In the thread Beigene Ltd ADR diskutieren
BeiGene is a Buy, as the stock is currently over 25% off its high!
Validation came in the form of a global collaboration deal signed with Celgene to commercialize PD-1 inhibitor BGB-A137. The specifics of the deal were interesting, with BeiGene management wisely
licensing rights in China to Celgene's next generation CelMod for lymphoma and hepatocellular carcinoma, CC-122. The financial terms were very generous, with BeiGene to receive upfront licensing fees of $263 million. The larger firm purchased 32.7 million shares at $59.55 per ADS (a 35% premium over the 11-day volume-weighted average price at the time).
(Laufzeit überschritten)
Stopped prediction by marge for BeiGene Ltd ADR
BeiGene Ltd ADR
Start price
Target price
Perf. (%)
€120.88
01.01.19
01.01.19
€250.00
04.11.21
04.11.21
166.39%
05.11.21
05.11.21